| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 10263.3 | 9150.4 | 8285.7 |
| Other income | 168.2 | 264.2 | 120.6 |
| Total income | 10431.5 | 9414.6 | 8406.3 |
| Profit before exceptional items & tax | 1687.7 | 1555.3 | 1275.9 |
| Exceptional items | 0.0 | -40.2 | 0.0 |
| Profit before tax | 1687.7 | 1515.1 | 1275.9 |
| Net profit | 1123.8 | 1032.0 | 848.1 |
| Operating margin | 16.2% | 16.1% | 15.2% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +32.50% |
|---|---|
| Net profit, quarter on quarter | +8.90% |
| Revenue, year on year | +23.90% |
| Operating profit, year on year | +31.50% |
| Operating profit, quarter on quarter | +17.70% |
NSE results filing, NSE: AUROPHARMA. Figures extracted from the filing.
Aurobindo Pharma Ltd: key numbers
- Share price
- ₹1,705.00
- Market cap
- ₹99,027 Cr
- Revenue (annual)
- ₹33,653 Cr
- Net profit (annual)
- ₹3,505 Cr
- P/E (TTM)
- 25.1×Sector 37.9×
- Promoter holding
- 51.88%+0.00% QoQ
- FII holding
- 17.41%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aurobindo Pharma Ltd
All →Aurobindo Pharma Acquisition Worth ₹29 Cr
Aurobindo's subsidiary Auropharm Overseas will buy 100% of Auro Pharma LLC, a Russian step-down subsidiary, for about Rs 29 crore cash. It is an internal group reorganisation.
- Value
- ₹29.00 Cr
- Execution
- 60-90 days
Aurobindo Pharma Management Change
Aurobindo Pharma's board approved reappointing independent director Mangalam Ramasubramanian Kumar for a second five-year term from April 1, 2027. Shareholder approval by postal ballot is required.
- Execution
- Five years from April 1, 2027
Aurobindo Pharma Merger & Restructuring Worth ₹29 Cr
Aurobindo Pharma approved transferring 100% of Auro Pharma LLC, Russia, between wholly owned subsidiaries. Cash consideration is about INR 29 crore, subject to adjustments.
- Value
- ₹29.00 Cr
- Execution
- 60-90 days
Aurobindo Pharma Acquisition
Aurobindo Pharma announced a board-approved proposal to merge two wholly owned subsidiaries, Auroactive Pharma into Apitoria Pharma, via NCLT scheme. No cash consideration; the share-exchange ratio issues 23,95,900 shares of Apitoria.
Aurobindo Pharma Dividend
Aurobindo Pharma declared an interim dividend of Rs 7.00 per share for FY27. Record date is 11 November 2026, with payment on or before 20 November.
Aurobindo Pharma Investor Presentation: Key Takeaways
Q2FY27 revenue ₹10,263 Cr (+23.9% YoY), record EBITDA ₹2,156 Cr at 21.0% margin, PAT ₹1,124 Cr (+32.5% YoY). Lannett acquisition completed.